689: 17-alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies

Abstract

ObjectiveProgesterone is associated with metabolic alterations that promote insulin resistance. The objective of this study was to compare the rate of GDM among women who received 17 alpha hydroxyprogesterone caproate (17OHPC) versus placebo.Study DesignThis is a secondary analysis of two double-blind randomized placebo-controlled trials of 17OHPC given to women at risk for preterm delivery (prior preterm birth or twins). Gestational diabetes (GDM) was defined by standard criteria and ascertained by medical chart abstraction. The prevalence of GDM was compared between women who received 17OHPC or placebo using a stratified analysis and multivariable logistic regression. Statistical significance was set at P <0.05.Results1111 women were included in the analysis; 629 women received 17OHPC and 482 received placebo. 458 women had singletons and 653 had twins. Demographic characteristics were similar between respective study populations. Among singleton and twin pregnancies, there was no difference in the rate of GDM in women receiving 17OHPC versus placebo (singletons, 5.6% vs. 4.6%, p= 0.67; twins 7.4% vs 7.6%, p =0.94). After multivariable logisitic regression, progesterone did not increase the odds of GDM, adjusted for study, obesity, race, and maternal age.ConclusionTabled 1Odds Ratio95% CIMaternal Age1.101.06-1.15Obesity (BMI >30 kg/m2)3.402.02-5.72Single/Twin Pregnancy1.150.64-2.05Race (African American)1.090.60-1.98Progesterone Use1.000.61-1.66 Open table in a new tab ObjectiveProgesterone is associated with metabolic alterations that promote insulin resistance. The objective of this study was to compare the rate of GDM among women who received 17 alpha hydroxyprogesterone caproate (17OHPC) versus placebo. Progesterone is associated with metabolic alterations that promote insulin resistance. The objective of this study was to compare the rate of GDM among women who received 17 alpha hydroxyprogesterone caproate (17OHPC) versus placebo. Study DesignThis is a secondary analysis of two double-blind randomized placebo-controlled trials of 17OHPC given to women at risk for preterm delivery (prior preterm birth or twins). Gestational diabetes (GDM) was defined by standard criteria and ascertained by medical chart abstraction. The prevalence of GDM was compared between women who received 17OHPC or placebo using a stratified analysis and multivariable logistic regression. Statistical significance was set at P <0.05. This is a secondary analysis of two double-blind randomized placebo-controlled trials of 17OHPC given to women at risk for preterm delivery (prior preterm birth or twins). Gestational diabetes (GDM) was defined by standard criteria and ascertained by medical chart abstraction. The prevalence of GDM was compared between women who received 17OHPC or placebo using a stratified analysis and multivariable logistic regression. Statistical significance was set at P <0.05. Results1111 women were included in the analysis; 629 women received 17OHPC and 482 received placebo. 458 women had singletons and 653 had twins. Demographic characteristics were similar between respective study populations. Among singleton and twin pregnancies, there was no difference in the rate of GDM in women receiving 17OHPC versus placebo (singletons, 5.6% vs. 4.6%, p= 0.67; twins 7.4% vs 7.6%, p =0.94). After multivariable logisitic regression, progesterone did not increase the odds of GDM, adjusted for study, obesity, race, and maternal age. 1111 women were included in the analysis; 629 women received 17OHPC and 482 received placebo. 458 women had singletons and 653 had twins. Demographic characteristics were similar between respective study populations. Among singleton and twin pregnancies, there was no difference in the rate of GDM in women receiving 17OHPC versus placebo (singletons, 5.6% vs. 4.6%, p= 0.67; twins 7.4% vs 7.6%, p =0.94). After multivariable logisitic regression, progesterone did not increase the odds of GDM, adjusted for study, obesity, race, and maternal age. ConclusionTabled 1Odds Ratio95% CIMaternal Age1.101.06-1.15Obesity (BMI >30 kg/m2)3.402.02-5.72Single/Twin Pregnancy1.150.64-2.05Race (African American)1.090.60-1.98Progesterone Use1.000.61-1.66 Open table in a new tab